UNSPSC 51182045: Rosterolone

This classification denotes a therapeutic androgen, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3L5C5C8ZNG. European Medicines Agency schedules Rosterolone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10390MIG. Rosterolone generally arises in the molecular formula C23H38O2.

UNSPSC 51182045 Rosterolone is a Commodity code covering generic pharmaceutical products supplied through state and local cooperative purchasing vehicles. State and local governments procure this product primarily through multistate cooperative purchasing alliances that establish master agreements with pharmaceutical manufacturers and wholesalers, enabling participating jurisdictions—state agencies, counties, municipalities, and health systems—to access negotiated pricing and standardized product availability. The work involves manufacturers certifying compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintaining relationships with authorized pharmaceutical wholesalers, and providing comprehensive product information including National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage forms, and packaging configurations. Vendors must demonstrate pricing flexibility through fixed pricing, net price formats, or WAC-minus pricing structures, carry substantial insurance coverage (commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000), and accept performance penalties for late reporting, missed onboarding timelines, or improper class-of-trade denials.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued the primary recent solicitation—a Request for Proposal (S1070000015802) with a response deadline of March 26, 2026 and a question cutoff of February 18, 2026. The RFP establishes multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors supplied to three authorized wholesalers (AmerisourceBergen Drug Corporation / Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) by May 15, 2026 and contracts effective July 1, 2026. Evaluation is weighted heavily toward price competitiveness (75 percent), with remaining points allocated to fixed pricing (10 percent), compliance with administrative data format requirements (5 percent), EDI capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). The contract term is two years for new responders with optional extensions at MMCAP's discretion, while incumbent amendments align with existing agreement expirations through June 30, 2028. No specific set-asides or award values are disclosed.